Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis - 06/09/22
Doi : 10.1016/j.jinf.2022.05.044
Mingyang Yang a, b, 1, Toni Li c, 1, Lihai Jiang d, 1, Yushu Wang e, Carolyn Tran f, Guangyu Ao g, ⁎ 
a West China Fourth Hospital/West China School of Public Health, Sichuan University, Chengdu, Sichuan, China
b Health Emergency Management Research Center, China-PUMC C.C. Chen Institute of Health, Sichuan University, Chengdu, Sichuan, China
c School of Medicine, Queen's University, Kingston, Canada
d Department of Urology, Chengdu First People's Hospital, Chengdu, Sichuan, China
e Chengdu West China Clinical Research Center, Chengdu, Sichuan, China
f Schulich School of Medicine & Dentistry, Western University, London, Canada
g Department of Nephrology, Chengdu First People's Hospital, No.18 Wanxiang North Road, High-tech District, Chengdu, Sichuan 610095, China
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | All studies compared the impact of regdanvimab on clinical outcomes. |
• | A total of 7 articles comprising 3333 adult patients with COVID-19 were included in the analysis. |
• | Outcomes suggested that regdanvimab administration reduces the risk of disease aggravation and death among COVID-19 patients. |
Keywords : COVID-19, Regdanvimab, Mortality, SARS-CoV-2
Plan
© 2022
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 85 - N° 4
P. e122-e124 - octobre 2022 Retour au numéro
Article précédent
- Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study
- Yue Yin, Xinjie Li, Chungen Qian, Bangning Cheng, Fengmin Lu, Tao Shen
Bienvenue sur EM-consulte, la référence des professionnels de santé.